Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04247581 · ClinicalTrials.gov registry record · NA
ECG App Algorithms Clinical Validation Study
A NA study, sponsored by Apple.
- Completed
- Registry status
- NA
- Development phase
- 546
- Enrollment target
NCT04247581: Completed NA study, sponsored by Apple.
NCT04247581 is a NA study that has completed, run by Apple. The registered enrollment target is 546 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (61% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04247581, a NA study, has completed, sponsored by Apple.
- COMPLETED
- Registry status
- NA
- Development phase
- 546 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the performance of ECG classification algorithms and their ability to classify heart rhythms into multiple categories of rhythms and heart rates
Primary Outcome
Specificity of sinus rhythm classification
Interventions
- DEVICE 1-lead ECG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 546 participants |
| Start Date | 2020-01-07 |
| Est. Completion | 2020-03-20 |
| Phase | NA |
What the finished NCT04247581 record still lists
NCT04247581 is an interventional study that assigns participants to a tested intervention. The registered 546 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (61% lower).
The record links to 0 conditions, and to 1 intervention - of which 1-lead ECG is the first listed.
NCT04247581 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04247581 about?
NCT04247581 is a clinical study titled "ECG App Algorithms Clinical Validation Study". The purpose of the study is to evaluate the performance of ECG classification algorithms and their ability to classify heart rhythms into multiple categories of rhythms and heart rates
What is the current status of trial NCT04247581?
This trial is currently completed. It is a NA study. The enrollment target is 546 participants. The study started on 2020-01-07. Estimated completion is 2020-03-20.
What interventions are being tested in trial NCT04247581?
The interventions under investigation include: 1-lead ECG (DEVICE).
Who is sponsoring clinical trial NCT04247581?
This trial is sponsored by Apple, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04247581's enrollment target sits among peer trials
546 186th of 2000 higher than 1,815 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03572374 · 546 participants · NA
Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job
- NCT05937685 · 546 participants · NA
Reducing Blood Pressure in Patients With High Cardiovascular Risk
- NCT06416150 · 546 participants · NA
Reducing Urban Cervical Cancer Disparities
- NCT06850922 · 546 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI